SCHEMBL7084865

SCHEMBL7084865

Cc1ccccc1CC(=O)Nc1ccc(Cl)cc1C(=O)C[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPT P10636 2/20 0.45
LPAR1 Q92633 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
HTT P42858 1/20 0.42
P2RX4 Q99571 1/20 0.42
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7085598 0.84 SMN1; SMN2 (0.48) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL7088124 0.81 KMT2A (0.59) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL7085104 0.81 KMT2A (0.51) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL7089003 0.80 KMT2A (0.53) KDM4EMAPTMEN1KMT2AALDH1A1
SCHEMBL7084919 0.79 CA1 (0.50) GAAMAPTMEN1KMT2ALMNA
SCHEMBL9640825 0.78 KDM4E (0.61) GAAKDM4EMAPTMEN1KMT2A
SCHEMBL7088236 0.77 KMT2A (0.50) GAAKDM4EMAPTMEN1KMT2A
SCHEMBL27531703 0.77 LPAR1 (0.46) GAAKDM4EMAPTLPAR1MEN1
SCHEMBL8211833 0.74 KMT2A (0.49) GAAKDM4EMAPTMEN1KMT2A
SCHEMBL12323599 0.72 HPGD (0.62) MAPTMEN1KMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
CN-1257474-A New nitromethylketone compounds, process for their preparation and compositions containing them MERCK PATENT GMBH (DE) 2000-06-21 CN disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 GAA 231/4885KDM4E 1913/4885MAPT 3746/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 GAA 998/4885KDM4E 329/4885MAPT 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.